Amgen Inc. Unrealized Gain (Loss) on Investments
Amgen Inc. (AMGN) reported Unrealized Gain (Loss) on Investments of -$301.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-08-05
- Amgen Inc. unrealized gain (loss) on investments for the quarter ending 2026-06-30 was -$158.00M.
- Amgen Inc. unrealized gain (loss) on investments for the quarter ending 2026-03-31 was -$143.00M, a 111.04% decline year-over-year.
- Amgen Inc. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was -$648.00M.
- Amgen Inc. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $1.97B, a 20.70% increase year-over-year.
- Amgen Inc. unrealized gain (loss) on investments for fiscal 2025 was $2.06B.
- Amgen Inc. unrealized gain (loss) on investments for fiscal 2024 was -$159.00M, a 110.16% decline from fiscal 2023.
- Amgen Inc. unrealized gain (loss) on investments for fiscal 2023 was $1.56B.
- Amgen Inc. unrealized gain (loss) on investments for fiscal 2022 was -$127.00M.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$158.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$301.00M 10-Q · filed 2026-08-05 | -$949.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.02B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$143.00M 10-Q · filed 2026-05-01 | -$791.00M derived: sum of 2 quarters · filed 2026-05-01 | $1.18B derived: sum of 3 quarters · filed 2026-05-01 | $626.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$648.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $1.32B derived: sum of 2 quarters · filed 2026-02-13 | $769.00M derived: sum of 3 quarters · filed 2026-08-05 | $2.06B 10-K · filed 2026-02-13 |
| 2025-09-30 | $1.97B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.42B derived: sum of 2 quarters · filed 2026-08-05 | $2.71B 10-Q · filed 2025-11-05 | $1.84B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$554.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $741.00M 10-Q · filed 2026-08-05 | -$135.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.50B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.29B 10-Q · filed 2026-05-01 | $419.00M derived: sum of 2 quarters · filed 2026-05-01 | $2.05B derived: sum of 3 quarters · filed 2026-05-01 | $1.65B derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | -$876.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $757.00M derived: sum of 2 quarters · filed 2026-02-13 | $356.00M derived: sum of 3 quarters · filed 2026-02-13 | -$159.00M 10-K · filed 2026-02-13 |
| 2024-09-30 | $1.63B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.23B derived: sum of 2 quarters · filed 2025-11-05 | $717.00M 10-Q · filed 2025-11-05 | $978.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | -$401.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$916.00M 10-Q · filed 2025-08-06 | -$655.00M derived: sum of 3 quarters · filed 2026-02-13 | -$520.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | -$515.00M 10-Q · filed 2025-05-02 | -$254.00M derived: sum of 2 quarters · filed 2026-02-13 | -$119.00M derived: sum of 3 quarters · filed 2026-02-13 | -$780.00M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | $261.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $396.00M derived: sum of 2 quarters · filed 2026-02-13 | -$265.00M derived: sum of 3 quarters · filed 2026-02-13 | $1.56B 10-K · filed 2026-02-13 |
| 2023-09-30 | $135.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$526.00M derived: sum of 2 quarters · filed 2024-10-31 | $1.30B 10-Q · filed 2024-10-31 | $1.29B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$661.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.17B 10-Q · filed 2024-08-07 | $1.16B derived: sum of 3 quarters · filed 2025-02-14 | $1.36B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $1.83B 10-Q · filed 2024-05-03 | $1.82B derived: sum of 2 quarters · filed 2025-02-14 | $2.02B derived: sum of 3 quarters · filed 2025-02-14 | $1.91B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | -$14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $195.00M derived: sum of 2 quarters · filed 2025-02-14 | $84.00M derived: sum of 3 quarters · filed 2025-02-14 | -$127.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | $209.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $98.00M derived: sum of 2 quarters · filed 2023-10-31 | -$113.00M 10-Q · filed 2023-10-31 | |
| 2022-06-30 | -$111.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$322.00M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | -$211.00M 10-Q · filed 2023-04-28 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |